Evidence map›Paper›PMID 39259324›Full record

SynthesisInternational journal of clinical oncology2024

Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.

Toshinobu Hayashi, Shun Yamamoto, Yoshiharu Miyata, Masayuki Takeda, Masakazu Abe, Makoto Wada, Keiko Iino, Tatsuo Akechi, Chiyo K Imamura, Ayako Okuyama and 18 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Toshinobu HayashiDepartment of Emergency and Disaster Medical Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan. toshinobu@fukuoka-u.ac.jp.ORCID http://orcid.org/0000-0001-6183-4939
Shun YamamotoDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yoshiharu MiyataDepartment of Artificial Intelligence and Digital Health Science, Kobe University Graduate School of Medicine, 7-1-48 Minatojimaminamimachi, Chuo-ku, Kobe, 650-0047, Japan.
Masayuki TakedaDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8521, Japan.
Masakazu AbeDepartment of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-Ku, Hamamatsu, Shizuoka, 431-3192, Japan.
Makoto WadaDepartment of Psycho-Oncology, Osaka International Cancer Institute, 3-1-69 Chuo-Ku, Osaka, 541-8567, Japan.
Keiko IinoSchool of Nursing, National College of Nursing, Japan, 1-2-1, Umezono, Kiyose, Tokyo, 204-8575, Japan.
Tatsuo AkechiDepartment of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, 467-8601, Japan.
Chiyo K ImamuraAdvanced Cancer Translational Research Institute, Showa University, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo, 142-8555, Japan.
Ayako OkuyamaGraduate School of Nursing Science, St. Luke's International University, 10-1 Akashi-Cho, Chuo-Ku, Tokyo, 104-0044, Japan.
Keiko OzawaDivision of Survivorship Institute for Cancer Control, National Cancer Center, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Yong-Il KimDivision of Medical Oncology, Yodogawa Christian Hospital, 1-7-50 Kunijima, Higasiyodogawa-Ku, Osaka, Osaka, 533-0024, Japan.
Hidenori SasakiDivision of Medical Oncology, Hematology and Infectious Disease, Fukuoka University Hospital, 7-45-1, Nanakuma, Jonan-Ku, Fukuoka, 814-0180, Japan.
Eriko SatomiDepartment of Palliative Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Ryuhei TanakaDepartment of Pediatric Hematology/Oncology, International Medical Center, Saitama Medical University, 1398-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
Takako Eguchi NakajimaDepartment of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawahara-Cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Naoki NakamuraDepartment of Radiation Oncology, St. Marianna University, 2-16-1, Sugao, Miyamae, Kawasaki, 216-8511, Japan.
Junichi NishimuraDepartment of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Osaka, 541-8567, Japan.
Mayumi NodaNon-Profit Organizaition Sasaeau-KaiAlpha, 518-7 Kawado-Cho, Chuo-Ku, Chiba, Chiba, 260-0802, Japan.
Kazumi HayashiDepartment of Clinical Oncology and Hematology, Jikei University School of Medicine, 3-25-8 Nishi-Shinnbashi Minatoku, Tokyo, 105-8461, Japan.
Takahiro HigashiDepartment of Public Health and Health Policy, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan.
Narikazu BokuDepartment of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, 4-6-1 Shiroganedai, Minato-Ku, Tokyo, 108- 8639, Japan.
Koji MatsumotoDivision of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-Cho, Akashi, Hyogo, 673-0021, Japan.ORCID http://orcid.org/0000-0003-1907-0247
Yoko MatsumotoNon-Profit Organization Ehime Cancer Support Orange-No-Kai, 3-8-24 Furukawaminami, Matsuyama, Ehime, 790-0943, Japan.
Kenji OkitaDepartment of Surgery, Otaru Ekisaikai Hospital, 1-4-1 Inaho, Otaru, Hokkaido, 047-0032, Japan.
Nobuyuki YamamotoInternal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama, 641-8509, Japan.
Kenjiro AogiDepartment of Breast Surgery, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-Machi, Matsuyama, Ehime, 791-0280, Japan.
Hirotoshi IiharaDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemotherapy-induced nausea and vomiting (CINV) commonly affects patient quality of life and the overall effectiveness of chemotherapy. This study aimed to evaluate whether adding neurokinin-1 receptor antagonists (NK1RAs) to 5-hydroxytryptamine-3 receptor antagonists (5-HT

methodsWe conducted a systematic review of PubMed, Cochrane Library, and Ichushi-Web to identify clinical studies evaluating NK1RAs combined with 5-HT

resultsFrom 142 articles identified, 15 randomized controlled trials (RCTs), involving 4,405 patients, were included in the meta-analysis. Approximately 60% of the patients received carboplatin (CBDCA)-based chemotherapy. The meta-analysis showed that triplet antiemetic prophylaxis with NK1RA was significantly more effective for achieving CR than doublet prophylaxis in each phase. Regarding CC, the triplet antiemetic prophylaxis was significantly more effective than the doublet in the overall (risk difference [RD]: 0.11, 95% confidence interval [CI]: 0.06-0.17) and delayed (RD: 0.08, 95% CI: 0.02-0.13) phases. For TC, no significant differences were observed in any phase. Adding NK1RA did not cause adverse events.

conclusionsAdding NK1RA to CBDCA-based chemotherapy has shown clinical benefits. However, the clinical benefits of NK1RA-containing regimens for overall MEC have not yet been established and require RCTs that exclusively evaluate MEC regimens other than CBDCA-based chemotherapy.

Indexed as

AntiemeticsAntineoplastic Combined Chemotherapy ProtocolsNauseaNeurokinin-1 Receptor AntagonistsVomitingAntineoplastic AgentsDexamethasoneHumansJapanMedical OncologyNeoplasmsPractice Guidelines as TopicQuality of LifeRandomized Controlled Trials as TopicSerotonin 5-HT3 Receptor AntagonistsAntiemeticsAntineoplastic AgentsDexamethasoneNeurokinin-1 Receptor AntagonistsSerotonin 5-HT3 Receptor AntagonistsAntiemeticsCarboplatinChemotherapy-induced nausea and vomitingModerately emetogenic chemotherapyNeurokinin-1 receptor antagonistSystematic review and meta-analysis

Identifiers

PMID39259324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.